Biomaterials startup Spiderwort designed the product, which uses a plant-based cellulose scaffold to promote spinal cord tissue regeneration after traumatic injuries.
The designation will “increase the speed at which we will initiate our clinical trials,” CEO and co-founder Charles Cuerrier said in a Nov. 12 announcement.
Spiderwort is preparing for a Series A financing round in 2021 as it moves closer to clinical trials.
More articles on biologics:
The most controversial trends in spine from 10 surgeons
Dr. Ali Baaj to build UArizona-Banner spine program from scratch in new role
Investment firm bets big on spine device company that rejected Stryker takeover
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
